{"database":"biostudies-literature","file_versions":[],"scores":null,"additional":{"submitter":["Haarberg HE"],"funding":["NCI NIH HHS"],"pagination":["27-32"],"full_dataset_link":["https://www.ebi.ac.uk/biostudies/studies/S-EPMC4031441"],"repository":["biostudies-literature"],"omics_type":["Unknown"],"volume":["11"],"pubmed_abstract":["The use of small molecule BRAF inhibitors has revolutionized the treatment of advanced melanoma. Despite this, resistance is commonplace and associated with a median progression-free survival of >5 months. Major resistance mechanisms include reactivation of the MAPK pathway and increased PI3K/AKT signaling. Here we review some of the combination therapeutic strategies currently undergoing evaluation for the management of acquired drug resistance in melanoma."],"journal":["Drug discovery today. Technologies"],"pubmed_title":["Resistance to Raf inhibition in cancer."],"pmcid":["PMC4031441"],"funding_grant_id":["R01 CA161107","R01 CA161107-01","P50 CA168536"],"pubmed_authors":["Smalley KS","Haarberg HE"],"additional_accession":[]},"is_claimable":false,"name":"Resistance to Raf inhibition in cancer.","description":"The use of small molecule BRAF inhibitors has revolutionized the treatment of advanced melanoma. Despite this, resistance is commonplace and associated with a median progression-free survival of >5 months. Major resistance mechanisms include reactivation of the MAPK pathway and increased PI3K/AKT signaling. Here we review some of the combination therapeutic strategies currently undergoing evaluation for the management of acquired drug resistance in melanoma.","dates":{"release":"2014-01-01T00:00:00Z","publication":"2014 Mar","modification":"2021-02-19T19:52:39Z","creation":"2020-11-07T09:47:45Z"},"accession":"S-EPMC4031441","cross_references":{"pubmed":["24847650"],"doi":["10.1016/j.ddtec.2013.12.004"]}}